◾ Canagliflozin is an insulin-independent, oral glucose-lowering agent. As an inhibitor of sodium glucose co-transporter 2 (SGLT2), canagliflozin causes urinary glucose excretion, which results in lowered blood glucose, weight loss, and blood pressure (BP) reduction 1 -CANA can be used as monotherapy when metformin is contraindicated or not tolerated ◾ The objective was to inform a multiple technology appraisal (MTA), to be conducted by the National Institute for Health and Care Excellence (NICE), on the use of SGLT2 inhibitors as monotherapies ◾ A systematic literature review (SLR) and Bayesian network meta-analysis (NMA) were conducted to assess the relative efficacy of canagliflozin for the treatment of adults with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise
INTRODUCTION & OBJECTIVES
◾ Canagliflozin is an insulin-independent, oral glucose-lowering agent. As an inhibitor of sodium glucose co-transporter 2 (SGLT2), canagliflozin causes urinary glucose excretion, which results in lowered blood glucose, weight loss, and blood pressure (BP) reduction 1 -CANA can be used as monotherapy when metformin is contraindicated or not tolerated ◾ The objective was to inform a multiple technology appraisal (MTA), to be conducted by the National Institute for Health and Care Excellence (NICE), on the use of SGLT2 inhibitors as monotherapies ◾ A systematic literature review (SLR) and Bayesian network meta-analysis (NMA) were conducted to assess the relative efficacy of canagliflozin for the treatment of adults with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise
METHODS
◾ Outcomes of interest included mean change from baseline in HbA1c, weight, and systolic BP (SBP) at 26 weeks (±4 weeks). The outcome measures chosen were in line with the standard outcome measures that were assessed in the randomised clinical trials in T2DM ◾ Bayesian NMAs were conducted based on the SLR. Methods were in line with NICE guidelines 2,3 ◾ Networks had treatment-and dose-specific nodes for dipeptidyl peptidase-4 (DPP- 4) inhibitors, pioglitazone, and agents that inhibit SGLT2, as some antihyperglycaemic agents (AHAs) have been shown to have a positive dose response. Doses of sulphonylurea (SU) were pooled to reflect dose adjustments on a per-patient basis ◾ Relative efficacy was evaluated based on absolute differences and Bayesian probabilities (P; i.e., probability to perform better). As there is no clear threshold for interpreting results in a Bayesian framework, for ease of presentation, 30% < P > 70% was chosen to indicate a smaller and larger effect, respectively ◾ The relative goodness of fit of the models was assessed using the deviance information criterion (DIC); the fixed-effects and random-effects models were estimated and the model associated with the lowest DIC was selected 4 ◾ Non-informative prior distributions were used to produce results that were driven by the data. Sensitivity analyses were performed to ensure that prior distributions for the between-trial precision of the random-effects models had no impact on the results, as recommended in NICE guidelines 3 ◾ Base case analyses were performed and included all relevant trials that were identified through the SLR. As ethnicity has been shown to influence efficacy estimates, in part due to variation in disease pathophysiology, 5 a sensitivity analysis that excluded single-ethnicity studies was performed (analysis reported as "reduced network")
RESULTS
◾ The SLR resulted in the identification of 38 trials that were suitable for inclusion in the base case analysis at 26 weeks (±4 weeks; Figure 1 ). Note that since the abstract submission, 2 additional trials were identified and included in the analysis; the updated results are reported here ◾ Two canagliflozin trials were included: a multinational study including both doses of canagliflozin (i.e., 100 and 300 mg) 1 and a study of canagliflozin 100 mg in Japanese patients 6 ◾ On the basis of the DIC, a random-effects model was selected for the analysis of HbA1c change from baseline, and a fixed-effects model was selected for the analysis of weight and SBP change from baseline
HbA1c Change From Baseline (Figure 2)
◾ All studies were included in the analysis of the mean change in HbA1c from baseline ◾ Canagliflozin 300 mg provided greater reductions in HbA1c versus other SGLT2 inhibitors; DPP-4 inhibitors; pioglitazone; and the SUs glimepiride, gliclazide, and glibenclamide, with HbA1c differences that ranged from -0.24% (P = 72%) versus glimepiride to -0.72% (P = 100%) versus vildagliptin 100 mg ◾ Canagliflozin 100 mg conferred greater reductions in HbA1c versus other SGLT2 inhibitors, DPP-4 inhibitors, pioglitazone 15 and 30 mg, and the SU gliclazide, with HbA1c differences that ranged from -0.12% (P = 71%) versus empagliflozin 25 mg to -0.49% (P = 99%) versus vildagliptin 100 mg. Canagliflozin 100 mg was associated with similar HbA1c reductions compared with pioglitazone 45 mg, glibenclamide, and glimepiride that ranged from -0.01% (P = 53%) versus glibenclamide to -0.05% (P = 62%) versus pioglitazone 45 mg ◾ Canagliflozin 300 mg was associated with similar HbA1c reductions (P = 39%) versus glipizide, and canagliflozin 100 mg was associated with lower HbA1c reductions (P = 24%) versus glipizide ◾ Clinicians reviewed the results and determined that the glipizide finding deserved further investigation, given that canagliflozin has been shown to perform favourably versus glimepiride, 7 an SU with better efficacy than glipizide. 8 The study of glipizide by Sami et al 9 included a population with high HbA1c levels at baseline (between 11% and 12% compared with <10% in other trials). Given that HbA1c at baseline is an important treatment effect modifier, 9 this study's population could explain the results in the comparison of canagliflozin and glipizide
Weight Change From Baseline
◾ A total of 18 studies could be included in the analysis of mean weight change from baseline, which assessed agents that inhibit SGLT2, DPP-4 inhibitors, and pioglitazone. No weight change data were available for SUs ◾ Canagliflozin provided greater reductions in weight (kg) versus all comparators, with weight differences of -0.39 kg (P = 88%) to -2.09 kg (P = 100%) versus SGLT2 inhibitors, -2.80 kg (P = 100%) to -4.55 kg (P = 100%) versus DPP-4 inhibitors, and -4.72 kg (P = 100%) to -7.17 kg (P = 100%) versus pioglitazone
SBP Change From Baseline
◾ Only 8 studies that assessed canagliflozin, dapagliflozin, empagliflozin, saxagliptin, sitagliptin, and pioglitazone 45 mg could be included in the analysis of mean SBP change from baseline ◾ Canagliflozin 300 mg had greater SBP reductions versus all comparators, which ranged from -2.01 mmHg (P = 96%) versus empagliflozin 25 mg to -7.61 mmHg (P = 100%) versus saxagliptin 5 mg ◾ Canagliflozin 100 mg was associated with similar or greater SBP reductions versus all comparators, which ranged from -0.31 mmHg (P = 60%) versus empagliflozin 25 mg to -5.92 mmHg (P = 99%) versus saxagliptin 5 mg
Sensitivity Analysis Excluding Single-ethnicity Trials
◾ A sensitivity analysis was conducted that excluded any single-ethnicity trials ("reduced network"). A total of 11 studies that focused on either Asian patients, Black/African-American patients, or Mexican-American patients were excluded, which resulted in the exclusion of glimepiride from the network ◾ Credibility intervals were broader due to the smaller number of trials that were included in the analysis; however, conclusions remained unchanged for canagliflozin 300 mg, and impacts on the point estimates were small (Figure 2) 
DISCUSSION
◾ Results of the sensitivity analysis ensured the robustness of the base case analysis results; the exclusion of trials focusing on a single ethnicity had small impacts on the results, and results were robust to the change of prior distributions for heterogeneity parameters in random-effects models (data not shown) ◾ The higher dose of canagliflozin (300 mg) was shown to consistently have better efficacy than the lower dose (100 mg) ◾ This NMA focused only on results at 26 weeks (±4 weeks); fewer comparator studies exist at later time points and it is anticipated that conclusions might differ somewhat versus some comparators. For example, long-term trials with canagliflozin have demonstrated a sustained response, 7, 11 whereas it is known that there is a progressive decrease in the effectiveness of SU with long-term use CrI, credible interval.
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